Submit

Login Login

Register Register

Home / Journals / BIOCELL / Online First / doi:10.32604/biocell.2024.048551
Journal Menu
Special lssues
Table of Content

All issues

Online First

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

2008

2007

2006

2005

2004

2003

2002

SAIB Annual Meetings

Open Access

ARTICLE

Amitriptyline inhibits NLRP3 inflammasome activation via the ASM/CE pathway in a cell model of NAFLD

QIN LIU1,#, CHUNYAN NIU2,#,*, QIANG ZHANG3, SHIQIN SUN4, YUE CHEN2, YONGQIANG SHI2
1 Shengli Clinical Medical College, Fujian Medical University, Fuzhou, 350001, China
2 Department of Gastroenterology, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, 211200, China
3 Department of Gastroenterology, Yancheng Third People’s Hospital (The Yancheng School of Clinical Medicine of Nanjing Medical University), Yancheng, 224000, China
4 Administrative Department of Teaching and Scientific Research, Nanjing Lishui People’s Hospital, Zhongda Hospital Lishui Branch, Southeast University, Nanjing, 211200, China
* Corresponding Author: CHUNYAN NIU. Email: email

BIOCELL https://doi.org/10.32604/biocell.2024.048551

Received 11 December 2023; Accepted 07 February 2024; Published online 20 March 2024

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is a global health concern with the acid sphingomyelinase (ASM)/ceramide (CE) pathway and the NOD-like receptor family, pyrin domain-containing protein 3 (NLRP3) inflammasome identified as pivotal players in lipid disorders and inflammation. This study explores the interaction mechanism between the ASM/CE pathway and NLRP3 in NAFLD cell models, aiming to understand the impact of amitriptyline (Ami), an ASM inhibitor, on lipid deposition and hepatocyte injury by regulating the ASM/CE-NLRP3 pathway. Methods: HepG2 and HL-7702 cells were exposed to free fatty acids (FFAs) to establish the NAFLD model. The cells were divided into 5 groups: control group, model group, Ami group, tumor necrosis factor-alpha (TNF-α) group, and Ami + TNF-α group. Intracellular lipid droplets were visualized using Oil Red O staining, and Western blot analysis quantified ASM, NLRP3, and caspase 1 protein expression. Enzyme linked immunosorbent assay (ELISA) was measured CE and ASM levels, while qRT-PCR assessed mRNA expression. The apoptotic rate was evaluated by flow cytometry (FCM). Results: Following FFAs incubation, significant increases in ASM and CE levels were observed in HepG2 and HL-7702 cells, accompanied by elevated expression of NLRP3, and caspase 1, and IL-1β. TNF-α treatment further amplified these indicators. Ami demonstrated a reduction in lipid deposition, suppressed ASM/CE pathway activation, downregulated NLRP3 and caspase 1 expression, and improved apoptosis. Additionally, MCC950, a selective inhibitor of the NLRP3, mitigated NLRP3, caspase 1, and IL-1β expression, alleviating lipid deposition and apoptosis in the NAFLD cell model. Conclusion: The ASM/CE-NLRP3 pathway in NAFLD cells promotes hepatocyte steatosis, inflammation, and cell damage. Ami emerges as a promising therapeutic agent by inhibiting the ASM/CE-NLRP3 pathway, underscoring its potential as a key target for NAFLD treatment.

Keywords

Nonalcoholic fatty liver disease; Hepatocyte; Amitriptyline; ASM/CE pathway; NLRP3; Nonalcoholic steatohepatitis

  • 279

    View

  • 66

    Download

  • 0

    Like

Related articles
Copyright© 2024 Tech Science Press
© 1997-2024 TSP (Henderson, USA) unless otherwise stated

Share Link